An observational study in Sudden Sensorineural Hearing Loss and Tinnitus, sponsored by The First Affiliated Hospital with Nanjing Medical University. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-09.
Sponsored by The First Affiliated Hospital with Nanjing Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Hearing Loss, Sudden with a site in China — 11 open to participants now, 11 under way, 1 of them phase 3. Hearing Loss, Sudden · China.
Among the 18 studies in Hearing Loss, Sudden with a site in China, this one is the only one that started in 2024, is one of 3 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 10th registered.
66 studies on the registry are indexed under Hearing Loss, Sudden; 25 are open to participants now.
Browse Hearing Loss, Sudden studies →11 of the 18 studies in Hearing Loss, Sudden with a site in China are open now. Recruiting first, the newest first:
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18–70
Guangdong Provincial People's Hospital · Sites in China
Ages 18–60
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–60
Beijing Tsinghua Chang Gung Hospital · Sites in China
Ages 18–70
Eye & ENT Hospital of Fudan University · Sites in China
Ages 12–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 10 Hearing Loss, Sudden studies recruiting now, 3 (30%) set no upper age limit and 5 (50%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 1 · Phase 4 1
First in 2019; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is close to the median of 82 across 14 observational studies indexed under Hearing Loss, Sudden.
Median enrollment 90 across the 15 interventional studies, 90 across the 3 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 18 have an industry lead sponsor. The 10 most frequent:
The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 569 studies on the registry; 317 are open to participants now.
The First Affiliated Hospital with Nanjing Medical University has 1 study filed under Hearing Loss, Sudden — fewer than ten, so there is no comparison to draw.
2 of the studies in Hearing Loss, Sudden with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07134075Eye & ENT Hospital of Fudan UniversityIntracochlear Injection of Glucocorticoid | 2027-08-01 |
| NCT07505667Guangdong Provincial People's HospitalYiyuancong for the Treatment of Sudden Sensorineural Hearing Loss | 2027-11-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Hearing Loss, Sudden with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate the factors and mechanisms underlying tinnitus generation and chronification in patients with sudden sensorineural hearing loss (SSNHL) . The main questions it aims to answer are:
Participants in this study will include patients with SSNHL and tinnitus, patients with SSNHL without tinnitus, and healthy subjects. They will be asked to undergo a series of assessments, including audiological tests, vestibular function examinations, and functional magnetic resonance imaging (fMRI). Additionally, blood samples will be collected for metabolomics analysis.
Investigators will compare the brain functional states and serum metabolite profiles of patients with SSNHL and tinnitus to those without tinnitus. Morever, tinnitus symptom characteristics, audiological outcomes, and brain functional states will be assessed during time.
The incidence rate of tinnitus is very high globally and shows an increasing trend year by year. Sudden sensorineural hearing loss (SSNHL) , a prevalent otolaryngological emergency, often coincides with tinnitus among its patient population. This condition can significantly impact individuals' interpersonal relationships, work performance, and daily functioning, ultimately leading to a diminished quality of life and even psychological disturbances, such as anxiety and depression. Consequently, it is imperative to expore the mechanisms underlying the emergence and chronicity of tinnitus following SSNHL, and to devise targeted intervention strategies aimed at preventing the chronicity of tinnitus.
This study aims to enroll 30 patients with SSNHL accompanied by tinnitus, 30 patients with SSNHL without tinnitus, and 30 healthy subjects. Investigators will record general demographic information, tinnitus symptom characteristics, audiological examinations, vestibular function tests, and other information for each group during the acute phase of SSNHL onset. Using functional magnetic resonance imaging (fMRI), investigators will compare the brain functional states of patients with SSNHL accompanied by tinnitus and those without tinnitus during the acute phase to investigate the peripheral influencing factors and central mechanisms of tinnitus production. Additionally, investigators will conduct metabolomics analysis to compare the serum metabolite profiles of these two patient groups to identify serum metabolic biomarkers and prognostic biomarkers for tinnitus in patients with SSNHL accompanied by tinnitus. Furthermore, this study will conduct follow-up assessments on the subjects at 1 month, 3 months, and 6 months after the onset of SSNHL, reviewing changes in their symptom characteristics, audiological examinations, and fMRI. At 6 months after the onset, patients will be divided into a tinnitus recovery group and a tinnitus non-recovery group based on their tinnitus recovery status. Investigators will compare the general demographic characteristics, audiological examinations, and brain functional MRI findings between the two groups to explore the role and mechanisms of brain plasticity changes in the recovery or chronicity of tinnitus in patients with SSNHL.
Patients with SSNHL and individuals undergoing physical examination at the Department of Otolaryngology, the First Affiliated Hospital of Nanjing Medical University
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Group of SSNHL with Tinnitus:
Group of SSNHL without Tinnitus:
Healthy Control:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with sudden sensorineural hearing loss accompanied with acute occuring tinnitus symptoms.
Other: Conventional treatment and care
Patients diagnosed with sudden sensorineural hearing loss without acute occuring tinnitus symptoms.
Other: Conventional treatment and care
Healthy subjects with normal hearing and no tinnitus.
Other: Conventional treatment and care
Conventional treatment and care
Brain function states
Fractional amplitude of low-frequency fluctuation, regional homogeneity, and functional connection will be compared among different groups using fMRI. Morever, the connections between the default mode network (DMN), central executive network (CEN), and salience network (SN) will be assessed through fMRI.
Time frame: Acute phase (within 5 days after onset), 1 month, 3 months, and 6 months after onset
Serum metabolomics
Serum metabolic profiles and characteristics will be gained and compared in patients SSNHL with or with tinnitus, using LC-MS metabolomics technology.
Time frame: Acute phase (within 5 days after onset)
Started Apr 2024 (actual). Primary completion is estimated for Dec 2025, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital with Nanjing Medical University →